Introduction {#tca13090-sec-0005}
============

Lung cancer has become one of the most common cancers worldwide, with high morbidity and mortality rates as most patients are not eligible for radical surgery at the time of diagnosis. Furthermore, traditional radiotherapy and chemotherapy have limited effects in cases of non‐small cell lung cancer (NSCLC). Recent research regarding targeted therapy such as epidermal growth factor receptor‐tyrosine kinase inhibitors (*EGFR*‐TKIs) and anaplastic lymphoma kinase inhibitors (*ALK*‐TKIs) has revealed significant improvements in overall survival rates of NSCLC patients harboring *EGFR* mutation or *ALK* rearrangement. As a result, targeted therapy has been approved as a first‐line treatment for these patients.[1](#tca13090-bib-0001){ref-type="ref"}, [2](#tca13090-bib-0002){ref-type="ref"}, [3](#tca13090-bib-0003){ref-type="ref"}, [4](#tca13090-bib-0004){ref-type="ref"}, [5](#tca13090-bib-0005){ref-type="ref"}, [6](#tca13090-bib-0006){ref-type="ref"}, [7](#tca13090-bib-0007){ref-type="ref"}, [8](#tca13090-bib-0008){ref-type="ref"}, [9](#tca13090-bib-0009){ref-type="ref"}, [10](#tca13090-bib-0010){ref-type="ref"}, [11](#tca13090-bib-0011){ref-type="ref"}, [12](#tca13090-bib-0012){ref-type="ref"}

Several studies have been performed to determine the current status of *EGFR‐*mutation/*ALK*‐rearrangement in Asia, including China. For example, Pan *et al.* [13](#tca13090-bib-0013){ref-type="ref"} analyzed 176 NSCLC patients treated at the First Affiliated Hospital of Wenzhou Medical College, and observed that the total mutation rate of the *EGFR* gene in exons 19, 20, and 21 was 48.3% (85/176). They further identified several factors, including female gender, adenocarcinoma, distant metastasis, and the chemotherapy, that may increase the probability of *EGFR* gene mutations. Shi *et al.* [14](#tca13090-bib-0014){ref-type="ref"} analyzed 747 patients with advanced NSCLC among a subset of patients from mainland China with an adenocarcinoma history as part of the PIONEER study, and found that the overall *EGFR* mutation rate was 50.2% among the 741 patients that were successfully genotyped, while the activating *EGFR* mutation rate was 48.0% (with 1.3% of patients showing combined activating and resistance mutations). Smoking history and regional lymph nodes involvement were identified as independent predictors of *EGFR* mutation in multivariate analysis. Zhou *et al.* [15](#tca13090-bib-0015){ref-type="ref"} analyzed *EGFR* mutations of 261 patients with pathologically confirmed NSCLC from West China Hospital, and observed that the *EGFR* mutation rate was 48.7%, with smoking status and pathological types as independent predictors. Fu *et al.* [16](#tca13090-bib-0016){ref-type="ref"} recruited 487 lung cancer patients who underwent testing for *ALK* rearrangement at Sun Yat‐sen University Cancer Center, and found that the *ALK* rearrangement rate was 9.0% (44/487), and that *ALK*‐rearranged NSCLC tended to occur in younger individuals who were either non‐smokers or light smokers with adenocarcinoma.

However, the current evaluation methods and periods of *EGFR* mutation and*/*or *ALK* rearrangement, as well as the first‐line targeted therapy rate in patients with NSCLC harboring *EGFR* mutations or *ALK* rearrangement in China remain unclear. Moreover, previous studies have been limited by their retrospective design. Therefore, we conducted a prospective multicenter study with the goal of determining the detection methods and detection periods of *EGFR* mutation and *ALK* rearrangement, the *EGFR* mutation rate, *ALK* rearrangement rate, and first‐line targeted therapy rate in patients with NSCLC harboring *EGFR* mutations or *ALK* rearrangement in northern China.

Methods {#tca13090-sec-0006}
=======

Study design and patients {#tca13090-sec-0007}
-------------------------

We conducted a prospective, epidemiological, multicenter, pan‐label, and non‐comparative study of *EGFR* mutation and *ALK* rearrangement evaluation status, and first‐line targeted therapy rate of patients with newly diagnosed advanced (stage IIIb--IV) NSCLC. This study only involved an observational protocol, and did not affect the patients' diagnosis and treatment. The study protocol was approved by the participating institutions' ethics committees. Patients who were eligible for enrollment provided written informed consent for participation in the study.

Patients with locally advanced or metastatic NSCLC (stage IIIb--IV) were enrolled at 12 hospitals in northern China between March 2015 and April 2017. The inclusion criteria were: (i) age ≥ 18 years, (ii) new diagnosis of NSCLC confirmed using histology or cytology, (iii) locally advanced or metastatic NSCLC (stage IIIb--IV or recurrent cases that were not eligible for surgery or radical chemoradiotherapy), (iv) simultaneous results for *EGFR* mutation and *ALK* rearrangement testing, and (v) no previous systemic treatment (except adjuvant chemotherapy). The exclusion criteria were: (i) previous non‐adjuvant systemic treatment, (iii) only sputum pathology specimens available, (iv) genetic results from sputum or blood samples, and (v) gene testing methods that did not fulfill the inclusion criteria.

Data collection {#tca13090-sec-0008}
---------------

Demographic and clinical characteristics of patients were collected, including age at diagnosis, gender, smoking status, date of first pathological diagnosis, method of pathological diagnosis, date that the first *EGFR* mutation and *ALK* rearrangement was confirmed, *EGFR*‐mutation/*ALK*‐rearrangement detection period (time from tumor diagnosis to *EGFR/ALK* status confirmation), detection method of *EGFR* mutation and *ALK* rearrangement, distant metastases, and first‐line treatment.

*EGFR*‐mutation and *ALK*‐rearrangement analysis {#tca13090-sec-0009}
------------------------------------------------

Tumor samples were obtained from primary or metastatic lesions, handled and stored following the respective laboratories' quality control requirements. The *EGFR*‐mutation was analyzed by amplification refractory mutation system (ARMS) or next‐generation sequencing (NGS), whereas the *ALK*‐rearrangement was analyzed by fluorescence *in situ* hybridization (FISH), NGS, or Ventana immunohistochemistry (IHC) targeting D5F3.

Statistical analyses {#tca13090-sec-0010}
--------------------

All statistical analyses were performed using IBM SPSS software (version 21.0; IBM Corp., Armonk, NY, USA). Continuous variables are expressed as the means ± standard deviation. Associations between mutations and demographic and clinical characteristics were analyzed by Fisher\'s exact tests. Characteristics significantly (*P* \< 0.05) associated with mutations were then included in a multivariate logistic model. The hazard ratio (HR) and 95%CI were calculated for all variables in the regression model. The correlation between first‐line targeted therapy and the *EGFR/ALK* detection period were analyzed by Spearman\'s correlation. All tests were two‐sided, and statistical significance was set at *P* \< 0.05. It is noteworthy that some patients underwent radical treatment and subsequently underwent *EGFR/ELK* gene testing several years after the diagnosis, which would not accurately reflect the *EGFR/ALK* detection period. Thus, the data from these cases were omitted from the related analyses of *EGFR/ALK* detection period.

Results {#tca13090-sec-0011}
=======

Patient characteristics {#tca13090-sec-0012}
-----------------------

Between March 2015 and April 2017, a total of 1134 patients with cytologically or histologically confirmed advanced NSCLC (stage IIIb--IV) were enrolled in the study at 12 Chinese hospitals. Among these patients, the most common pathological type was adenocarcinoma (973 cases), followed by squamous cell carcinoma (109 cases), unclassified carcinoma (36 cases), adenosquamous carcinoma (11 cases), sarcomatoid carcinoma (3 cases), and large cell carcinoma (2 cases). The specimens were evaluated using histology (976 cases) and cytology (158 cases). The cases involved primary lesions (757 cases) or metastatic lesions (377 cases), including 172 cases of distal/local lymph node metastases, 126 cases of pleural effusion, 25 cases of pleural metastasis, 21 cases of bone metastasis, 10 cases of liver metastasis, eight cases of brain metastasis, seven cases of subcutaneous nodule metastasis, and eight cases of other metastatic sites. The most common biopsy methods were bronchoscopy (395 cases) and computed tomography‐guided lung puncture (365 cases). The other cases involved ultrasound‐guided puncture (191 cases), bone biopsy (16 cases), surgical biopsy (133 cases), radical resection (32 cases), and cerebrospinal fluid collection (2 cases). The most common biopsy site was the lung (66.8%), the most common biopsy method was bronchoscopy (34.6%), and the most common metastatic site was the lung (22.6%). The cases of squamous NSCLC patients frequently involved male patients (92/109) who were \>60 years old (70/109), and patients with a smoking history (86/109). The cases of non‐squamous NSCLC patients involved male patients (550/1025) with a smoking history (430/1025), and patients who were \>60 years old (516/1025). Table [1](#tca13090-tbl-0001){ref-type="table"} summarizes the clinicopathological features of 1134 NSCLC patients, 1025 non‐squamous NSCLC patients, and 109 squamous NSCLC patients.

###### 

Clinical and pathological features of 1134 NSCLC patients

                       All patients   Non‐squamous    Squamous
  -------------------- -------------- --------------- --------------
  Age                                                 
  Medium (Range)       60 (21--88)    60 (21--88)     63 (42--87)
  ≤60 years old        548 (48.4%)    509 (49.7%)     39 (35.8%)
  \>60 years old       586 (51.6%)    516 (50.3%)     70 (64.2%)
  Gender                                              
  Male                 642 (56.6%)    550 (53.7%)     92 (84.4%)
  Female               492 (43.4%)    475 (46.3%)     17 (15.6%)
  Smoking history                                     
  No                   588 (51.9%)    565 (55.1%)     23 (21.1%)
  Yes                  515 (45.4%)    430 (42.0%)     85 (78.0%)
  Unknown              31 (2.7%)      30 (2.9%)       1 (0.9%)
  Stage                                               
  IIIb                 165 (14.6%)    120 (11.7%)     45 (41.3%)
  IV                   969 (85.4%)    905 (88.3%)     64 (58.7%)
  Pathology                                           
  Non‐squamous         1025 (90.4%)   1025 (100.0%)   0 (0.0%)
  Squamous             109 (9.6%)     0 (0.0%)        109 (100.0%)
  Diagnostic methods                                  
  Histology            976 (86.1%)    867 (84.6%)     109 (100.0%)
  cytology             158 (13.9%)    158 (15.4%)     0 (0.0%)
  EGFR mutation                                       
  Mutant type          461 (40.7%)    452 (44.1%)     9 (8.3%)
  Wild type            673 (59.3%)    573 (55.9%)     100 (91.7%)
  ALK rearrangement                                   
  Mutant type          107 (9.4%)     103 (10.0%)     4 (3.7%)
  Wild type            1027 (90.6%)   922 (90.0%)     105 (96.3%)

EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.

*EGFR/ALK* evaluation status {#tca13090-sec-0013}
----------------------------

Among all patients, the most commonly used methods of detection for *EGFR* mutation and *ALK* rearrangement were ARMS (1029/1134, 90.7%) and IHC targeting D5F3 (692/1134, 61.0%), respectively. Among patients with non‐squamous NSCLC, the most commonly used methods of detection for *EGFR* mutation and *ALK* rearrangement were ARMS (933/1025, 91.0%) and IHC targeting D5F3 (637/1025, 62.1%), respectively. Six cases were evaluated for *ALK* rearrangement using both NGS and IHC (2 cases) or both ARMS and IHC (4 cases), which revealed consistent findings. Twenty‐two cases were evaluated for *ALK* rearrangement using both FISH and IHC, which revealed consistent findings in 21 cases and inconsistent findings in one case (positive IHC results and negative FISH results). Among patients with squamous NSCLC, the most commonly used methods of detection for *EGFR* mutation and *ALK* rearrangement were ARMS (96/109 88.1%) and IHC targeting D5F3 (55/109, 50.1%), respectively. One cases were evaluated for *ALK* rearrangement using both ARMS and IHC, which revealed consistent findings. Two cases were evaluated for *ALK* rearrangement using both FISH and IHC, which revealed inconsistent findings (positive IHC results and negative FISH results).

The median time from the biopsy to tumor diagnosis was three days (range: 0--54 days). Sixty patients underwent genetic testing several years after undergoing radical therapy, which would not accurately reflect the *EGFR/ALK* detection period; thus, these cases were omitted from the following analyses. Among the remaining cases, the median time from tumor diagnosis to *EGFR* status confirmation was seven days (range: 0--84 days), with median times of seven days (range: 0--84 days) for ARMS and nine days (range: 0--42 days) for NGS. The median time from tumor diagnosis to *ALK* status confirmation was five days (range: 0--81 days), with median times of seven days (range: 0--81 days) for NGS, seven days (range: 0--55 days) for FISH, and four days (range: 0--42 days) for IHC.

*EGFR/ALK* evaluation results {#tca13090-sec-0014}
-----------------------------

Among all patients, the *EGFR* mutation rate was 40.7% (461/1134), with the major mutations being 19del and 21L858R. The sensitive mutation rate was 38.8% (440/1134) and the primary drug‐resistant mutation rate was 1.8% (21/1134). Nineteen patients (1.7%) had double *EGFR* mutations, with the most common being L858R and T790M (8/19) (Table [2](#tca13090-tbl-0002){ref-type="table"}). The *EML4‐ALK* rearrangement rate was 9.4% (107/1134), which included 100 adenocarcinomas, four squamous cell carcinomas, two adenosquamous carcinomas, and one NSCLC. Among patients with non‐squamous, the *EGFR* mutation rate was 44.1% (452/1025) and the *ALK* rearrangement rate was 10.0% (103/1025). Among patients with squamous cell carcinoma, the EGFR mutation rate was 8.3% (9/109) and the ALK rearrangement rate was 3.7% (4/109).

###### 

Mutation patterns of 19 cases with EGFR double mutations

  Pts.    19del   L858R   L861Q   G719X   S768I   T790M   20ins  G   Age   SH   P     TNM stage
  ------ ------- ------- ------- ------- ------- ------- ------- --- ----- ---- ---- -----------
  1         −       −       −      \+      \+       −       −    M   76    N    AS     T2N3M0
  2         −       −       −      \+      \+       −       −    F   54    N    A      T1N0M1
  3         −       −       −      \+      \+       −       −    M   60    Y    A      T4N2M1
  4         −       −       −      \+      \+       −       −    M   49    Y    A      T2N3M1
  5         −       −       −      \+      \+       −       −    F   51    N    A      T2N3M1
  6        \+       −       −      \+       −       −       −    F   68    Y    AS     T4N3M0
  7        \+       −       −       −       −      \+       −    F   58    Y    A      TXNXM1
  8        \+       −       −       −       −      \+       −    F   80    Y    A      T2N2M1
  9        \+      \+       −       −       −       −       −    F   65    Y    A      T2N0M1
  10               \+       −       −      \+       −       −    M   71    Y    A      T1N3M0
  11               \+       −       −      \+       −       −    M   59    Y    A      T1N3M1
  12               \+       −       −       −      \+       −    M   64    Y    A      T4N3M1
  13               \+       −       −       −      \+       −    M   66    Y    S      T4N2M1
  14               \+       −       −       −      \+       −    F   60    N    A      T1N1M1
  15               \+       −       −       −      \+       −    F   76    N    A      T4N3M1
  16               \+       −       −       −      \+       −    F   50    N    A      T3N2M1
  17               \+       −       −       −      \+       −    M   46    Y    A      T2N2M1
  18               \+       −       −       −      \+       −    F   76    N    A      T4N0M1
  19               \+       −       −       −      \+       −    M   66    N    A      T2N0M1

A, adenocarcinoma; AS, adenosquamous carcinoma; F, female; G, gender; M, male; N, no, never smoker; P, pathology; S, squamous carcinoma; SH, smoking history; Y, yes, former or current smoker.

Among all patients, univariate analyses showed that the *EGFR* mutation rate was significantly higher in females (*P* \< 0.001), without a smoking history (*P* \< 0.001), non‐squamous (*P* \< 0.001), stage IV tumor (*P* \< 0.001), bone metastases (*P* = 0.014), brain metastases (*P* = 0.002), pleural effusion (*P* = 0.016) and pleural nodules (*P* = 0.014) (Table [3](#tca13090-tbl-0003){ref-type="table"}). Multivariate analysis further identified gender (HR = 1.7, 95%CI = 1.2--2.4, *P* = 0.006), smoking history (HR = 1.8, 95%CI = 1.3--2.7, *P* = 0.001), histology (HR = 5.0, 95%CI = 2.4--10.1, *P* \< 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1--2.2, *P* = 0.017) as independent predictors of *EGFR* mutation. Among patients with non‐squamous , univariate analyses showed that the *EGFR* mutation rate was significantly higher in females (*P* \< 0.001), without a smoking history (*P* \< 0.001), stage IV tumor (*P* = 0.002), brain metastases (*P* = 0.027), and pleural nodules metastases (*P* = 0.034) (Table [4](#tca13090-tbl-0004){ref-type="table"}). Multivariate analysis further identified female (HR = 1.6, 95%CI = 1.1--2.3, *P* = 0.013), without a smoking history (HR = 1.9, 95%CI = 1.3--2.7, *P* = 0.001), and brain metastases (HR = 1.5, 95%CI = 1.1--2.1, *P* = 0.021) had higher *EGFR* mutation. Among patients with squamous, univariate analyses showed that the *EGFR* mutation rate was significantly higher in females (*P* = 0.004), without a smoking history (*P* = 0.049), and pleural effusion (*P* = 0.032) (Table [5](#tca13090-tbl-0005){ref-type="table"}). Multivariate analysis further identified only gender (HR = 6.0, 95%CI = 1.1--32.6, *P* = 0.040) as independent predictor of *EGFR* mutation.

###### 

Fisher exact probability method analysis of EGFR mutation and clinical characteristics in 1134 NSCLC patients

  Characteristics      No. (%)        Wild type (%)   Mutant type (%)   *P*‐value
  -------------------- -------------- --------------- ----------------- -----------
  Age                                                                   
  \<60 years old       548 (48.3%)    317 (57.8%)     231 (42.2%)       0.333
  ≥60 years old        586 (51.7%)    356 (60.8%)     230 (39.2%)       
  Gender                                                                
  Male                 642 (56.6%)    450 (70.1%)     192 (29.9%)       \<0.001
  Female               492 (43.4%)    223 (45.3%)     269 (54.7%)       
  Smoking history                                                       
  No                   588 (53.3%)    282 (48.0%)     30 (52.0%)        \<0.001
  Yes                  515 (46.7%)    380 (73.8%)     135 (26.2%)       
  Unknown              31             11              20                
  Pathology                                                             
  Non‐squamous         1025 (90.4%)   573 (55.9%)     452 (44.1%)       \<0.001
  Squamous             109 (9.6%)     100 (91.7%)     9 (8.3%)          
  T stage                                                               
  1                    153 (13.5%)    83 (54.2%)      70 (45.8%)        0.093
  2                    268 (23.6%)    154 (57.5%)     114 (42.5%)       
  3                    107 (9.4%)     72 (67.3%)      35 (32.7%)        
  4                    526 (46.4%)    323 (61.4%)     203 (38.6%)       
  x                    80 (7.1%)      41 (51.3)       39 (48.8)         
  N stage                                                               
  0                    161 (14.2%)    82 (50.9%)      79 (49.1%)        0.058
  1                    48 (4.2%)      26 (54.2%)      22 (45.8%)        
  2                    298 (26.3%)    174 (58.4%)     124 (41.6%)       
  3                    593 (52.3%)    373 (62.9%)     220 (37.1%)       
  x                    34 (3.0%)      18 (52.9%)      16 (47.1%)        
  M stage                                                               
  0                    166 (14.6%)    126 (75.9%)     40 (24.1%)        \<0.001
  1                    968 (85.4%)    547 (56.5%)     421 (43.5%)       
  Lung metastases                                                       
  No                   724 (63.8%)    442 (61.0%)     282 (39.0%)       0.131
  Yes                  410 (36.2%)    231 (56.3%)     179 (43.7%)       
  Bone metastases                                                       
  No                   733 (64.6%)    455 (62.1%)     278 (37.9%)       0.014
  Yes                  401 (35.4%)    218 (54.4%)     183 (45.6%)       
  Brain metastases                                                      
  No                   948 (16.4%)    582 (61.4%)     366 (38.6%)       0.002
  Yes                  186 (83.6%)    91 (48.9%)      95 (51.1%)        
  Adrenal metastases                                                    
  No                   1046 (92.2%)   613 (58.6%)     433 (41.4%)       0.090
  Yes                  88 (7.8%)      60 (68.2%)      28 (31.8%)        
  Liver metastases                                                      
  No                   1040 (91.7%)   610 (58.7%)     430 (41.3%)       0.125
  Yes                  94 (8.3%)      63 (67.0%)      31 (33.0%)        
  Pleural effusion                                                      
  No                   813 (71.7%)    501 (61.6%)     312 (38.4%)       0.016
  Yes                  321 (28.3%)    172 (53.6%)     149 (46.4%)       
  Pleural nodules                                                       
  No                   1002 (88.4%)   608 (60.7%)     394 (39.3%)       0.014
  Yes                  132 (11.6%)    65 (49.2%)      67 (50.8%)        

EGFR, epidermal growth factor receptor.

###### 

Fisher exact probability method analysis of EGFR mutation and clinical characteristics in 1025 non‐squamous NSCLC patients

  characteristics         No.           Wild type      Mutant type   *P*‐value
  ----------------------- ------------- -------------- ------------- -----------
  Age (N,%)                                                          
  \<60 years old          509 (49.7%)   285 (56.0%)    224 (44.0%)   1.000
  ≥60 years old           516 (50.8%)   288 (55.8%)    228 (44.2%)   
  Gender (N,%)                                                       
  Male                    550 (53.7%)   362 (65.8%)    188 (34.2%)   \<0.001
  Female                  475 (46.3%)   211 (44.4%)    264 (55.6%)   
  Smoking history (N,%)                                              
  No                      565 (55.1%)   264 (46.7%)    301 (53.3%)   \<0.001
  Yes                     430 (42.0%)   299 (69.5%))   131 (30.5%)   
  Unknown                 30 (2.9%)     10 (33.3%)     20 (66.7%)    
  T stage (N,%)                                                      
  1                       148 (14.4%)   78 (52.7%)     70 (47.3%)    0.415
  2                       247 (24.1%)   136 (55.1%)    111 (44.9%)   
  3                       96 (9.4%)     61 (63.5%)     35 (36.5%)    
  4                       457 (44.6%)   259 (56.7%)    198 (43.3%)   
  x                       77 (7.5%)     39 (50.6%)     38 (49.4%)    
  N stage (N,%)                                                      
  0                       154 (15.0%)   75 (48.7%)     79 (51.3%)    0.107
  1                       42 (4.1%)     21 (50.0%)     21 (50.0%)    
  2                       263 (25.7%)   142 (54.0%)    121 (46.0%)   
  3                       533 (52.0%)   318 (59.7%)    215 (40.3%)   
  x                       33 (3.2%)     17 (51.5%)     16 (48.5%)    
  M stage (N,%)                                                      
  0                       121 (14.6%)   84 (69.4%)     37 (30.6%)    0.002
  1                       904 (85.4%)   489 (54.1%)    415 (45.9%)   
  Lung metastases                                                    
  No                      645 (62.9%)   370 (57.4%)    275 (42.6%)   0.241
  Yes                     380 (37.1%)   203 (53.4%)    177 (46.6%)   
  Bone metastases                                                    
  No                      650 (63.4%)   378 (58.2%)    272 (41.8%)   0.058
  Yes                     375 (36.6%)   195 (52.0%)    180 (48.0%)   
  Brain metastases                                                   
  No                      841 (82.0%)   484 (57.6%)    357 (42.4%)   0.027
  Yes                     184 (18.0%)   89 (48.4%)     95 (51.6%)    
  Adrenal metastases                                                 
  No                      942 (91.9%)   518 (55.0%)    424 (45.0%)   0.050
  Yes                     83 (8.1%)     55 (66.3%)     28 (33.7%)    
  Liver metastases                                                   
  No                      938 (91.5%)   516 (55.0%)    422 (45.0%)   0.071
  Yes                     87 (8.5%)     57 (65.5%)     30 (34.5%)    
  Pleural effusion                                                   
  No                      721 (70.3%)   414 (57.4%)    307 (42.6%)   0.148
  Yes                     304 (29.7%)   159 (52.3%)    145 (47.7%)   
  Pleural nodules                                                    
  No                      901 (87.9%)   515 (57.2%)    386 (42.8%)   0.034
  Yes                     124 (12.1%)   58 (46.8%)     66 (53.2%)    

EGFR, epidermal growth factor receptor.

###### 

Fisher exact probability method analysis of EGFR mutation and clinical characteristics in 109 squamous NSCLC patients

  Characteristics         No.           Wild type     Mutant type   *P*‐value
  ----------------------- ------------- ------------- ------------- -----------
  Age (N,%)                                                         
  \<60 years old          39 (35.8%)    34 (87.2%)    5 (12.8%)     0.277
  ≥60 years old           70 (64.2%)    66 (94.3%)    4 (5.7%)      
  Gender (N,%)                                                      
  Male                    92 (84.4%)    88 (95.7%)    4 (4.3%)      0.004
  Female                  17 (15.6%)    12 (70.6%)    5 (29.4%)     
  Smoking history (N,%)                                             
  No                      23 (21.1%)    18 (78.3%)    5 (21.7%)     0.049
  Yes                     85 (78.0%)    81 (95.3%))   4 (4.7%)      
  Unknown                 1 (0.9%)      1 (100.0%)    0 (0.0%)      
  T stage (N,%)                                                     
  1                       5 (4.6%)      5 (100.0%)    0 (0.0%)      0.287
  2                       21 (19.3%)    18 (85.7%)    3 (14.3%)     
  3                       11 (10.1%)    11 (100.0%)   0 (0.0%)      
  4                       69 (63.3%)    64 (92.8%)    5 (7.2%)      
  x                       3 (2.8%)      2 (66.7%)     1 (33.3%)     
  N stage (N,%)                                                     
  0                       7 (6.4%)      7 (100.0%)    0 (0.0%)      0.743
  1                       6 (5.5%)      5 (83.3%)     1 (16.7%)     
  2                       35 (32.1%)    32 (91.4%)    3 (8.6%)      
  3                       60 (55.0%)    55 (91.7%)    5 (8.3%)      
  x                       1 (0.9%)      1 (100.0%)    0 (0.0%)      
  M stage (N,%)                                                     
  0                       45 (41.3%)    42 (93.3%)    3 (6.7%)      0.734
  1                       64 (58.7%)    58 (90.6%)    6 (9.4%)      
  Lung metastases                                                   
  No                      79 (72.5%)    72 (91.1%)    7 (8.9%)      1.000
  Yes                     30 (27.5%)    28 (93.3%)    2 (6.7%)      
  Bone metastases                                                   
  No                      83 (76.1%)    77 (92.8%)    6 (7.2%)      0.443
  Yes                     26 (23.9%)    23 (88.5%)    3 (11.5%)     
  Brain metastases                                                  
  No                      107 (98.2%)   98 (91.6%)    9 (8.4%)      1.000
  Yes                     2 (1.8%)      2 (100.0%)    0 (0.0%)      
  Adrenal metastases                                                
  No                      104 (95.4%)   95 (91.3%)    9 (8.7%)      1.000
  Yes                     5 (4.6%)      5 (100.0%)    0 (0.0%)      
  Liver metastases                                                  
  No                      102 (93.6%)   94 (92.2%)    8 (7.8%)      0.463
  Yes                     7 (6.4%)      6 (85.7%)     1 (14.3%)     
  Pleural effusion                                                  
  No                      92 (84.4%)    87 (94.6%)    5 (5.4%)      0.032
  Yes                     17 (15.6%)    13 (76.5%)    4 (23.5%)     
  Pleural nodules                                                   
  No                      101 (92.7%)   93 (92.1%)    8 (7.9%)      0.510
  Yes                     8 (7.3%)      7 (87.5%)     1 (12.5%)     

EGFR, epidermal growth factor receptor.

Among all patients, univariate analyses showed that the *ALK* rearrangement rate was significantly higher in patients who were ≤60 years old (*P* \< 0.001), female (*P* = 0.002), without a smoking history (*P* \< 0.001), and non‐squamous (*P* = 0.025) (Table [6](#tca13090-tbl-0006){ref-type="table"}). In multivariate analysis, only younger age (HR = 2.6, 95%CI = 1.7--4.1, *P* \< 0.001) was an independent predictor of *ALK* rearrangement. Among patients with non‐squamous patients, univariate analyses showed that the *ALK* rearrangement rate was significantly higher in patients who were ≤60 years old (*P* \< 0.001), female (*P* = 0.007), and without a smoking history (*P* = 0.001) (Table [7](#tca13090-tbl-0007){ref-type="table"}). In multivariate analysis, only younger age (HR = 2.7, 95%CI = 1.7--4.2, *P* \< 0.001) was an independent predictor of *ALK* rearrangement. Among patients with squamous, four cases involved IHC‐confirmed ALK, with negative FISH results in two cases and no FISH testing in the other two cases. All four patients were ≤60 years old, three were male, and three had smoking history.

###### 

Fisher exact probability method analysis of ALK rearrangement and clinical characteristics in 1134 NSCLC patients

  Characteristics          No.            Wild type     Mutant type   *P*‐value
  ------------------------ -------------- ------------- ------------- -----------
  Age (N, %)                                                          
  ≤60 years old            548 (48.0%)    473 (86.2%)   75 (13.8%)    \<0.001
  \>60 years old           586 (52.0%)    554 (94.6%)   32 (5.4%)     
  Gender (N,%)                                                        
  Male                     642 (56.6%)    597 (93.0%)   45 (7.0%)     0.002
  Female                   492 (43.4%)    430 (87.4%)   62 (12.6%)    
  Smoking history (N, %)                                              
  No                       588 (51.9%)    513 (87.2%)   75 (12.8%)    \<0.001
  Yes                      515 (45.4%)    484 (94.0%)   31 (6.0%)     
  Unknown                  31 (2.7%)      30 (96.8%)    1 (3.2%)      
  Pathology (N, %)                                                    
  Non‐squamous             1025 (90.4%)   922 (90.0%)   103 (10.0%)   0.025
  Squamous                 109 (9.6%)     105 (96.3%)   4 (3.7%)      
  T stage (N, %)                                                      
  1                        153 (13.5%)    135 (88.2%)   18 (11.8%)    0.586
  2                        268 (23.6%)    243 (90.7%)   25 (9.3%)     
  3                        107 (9.4%)     94 (87.9%)    13 (12.1%)    
  4                        526 (46.4%)    482 (91.6%)   44 (8.4%)     
  x                        80 (7.1%)      73 (91.3%)    7 (8.7%)      
  N stage (N, %)                                                      
  0                        161 (14.2%)    150 (93.2%)   11 (6.8%)     0.818
  1                        48 (4.2%)      44 (91.7%)    4 (8.3%)      
  2                        298 (26.3%)    269 (90.3%)   29 (9.7%)     
  3                        593 (52.3%)    533 (89.9%)   60 (10.1%)    
  x                        34 (3.0%)      31 (91.2%)    3 (8.8%)      
  M stage (N,%)                                                       
  0                        166 (14.6%)    150 (90.4%)   16 (9.6%)     0.886
  1                        968 (85.4%)    877 (90.6%)   91 (9.4%)     
  Lung metastases                                                     
  No                       724 (63.8%)    652 (90.1%)   72 (9.9%)     0.461
  Yes                      410 (36.2%)    375 (91.5%)   35 (8.5%)     
  Bone metastases                                                     
  No                       733 (64.6%)    656 (89.5%)   77 (10.5%)    0.111
  Yes                      401 (35.4%)    371 (92.5%)   30 (7.5%)     
  Brain metastases                                                    
  No                       948 (16.4%)    857 (90.4%)   91 (9.6%)     0.784
  Yes                      186 (83.6%)    170 (91.4%)   16 (8.6%)     
  Adrenal metastases                                                  
  No                       1046 (92.2%)   944 (90.2%)   102 (9.8%)    0.257
  Yes                      88 (7.8%)      83 (94.3%)    5 (5.7%)      
  Liver metastases                                                    
  No                       1040 (91.7%)   947 (91.1%)   93 (8.9%)     0.066
  Yes                      94 (8.3%)      80 (85.1%)    14 (14.9%)    
  Pleural effusion                                                    
  No                       813 (71.7%)    733 (90.2%)   80 (9.8%)     0.500
  Yes                      321 (28.3%)    294 (91.6%)   27 (8.4%)     
  Pleural nodules                                                     
  No                       1002 (88.4%)   910 (90.8%)   92 (9.2%)     0.428
  Yes                      132 (11.6%)    117 (88.6%)   15 (11.4%)    

ALK, anaplastic lymphoma kinase.

###### 

Fisher exact probability method analysis of ALK rearrangement and clinical characteristics in 1025 non‐squamous NSCLC patients

  Characteristics         No.           Wild type     Mutant type   *P*‐value
  ----------------------- ------------- ------------- ------------- -----------
  Age (N,%)                                                         
  \<60 years old          509 (49.7%)   436 (85.7%)   73 (14.3%)    \<0.001
  ≥60 years old           516 (50.3%)   486 (94.2%)   30 (5.8%)     
  Gender (N,%)                                                      
  Male                    550 (53.7%)   508 (92.4%)   42 (7.6%)     0.007
  Female                  475 (46.3%)   414 (87.2%)   61 (12.8%))   
  Smoking history (N,%)                                             
  No                      565 (55.1%)   491 (86.9%)   74 (13.1%)    0.001
  Yes                     430 (42.0%)   402 (93.5%)   28 (6.5%)     
  Unknown                 30 (2.9%)     29 (96.7%)    1 (3.3%)      
  T stage (N,%)                                                     
  1                       148 (14.4%)   130 (87.8%)   18 (12.2%)    0.700
  2                       247 (24.1%)   222 (89.9%)   25 (10.1%)    
  3                       96 (9.4%)     84 (87.5%)    12 (12.5%)    
  4                       457 (44.6%)   416 (91.0%)   41 (9.0%)     
  x                       77 (7.5%)     70 (90.0%)    7 (9.1%)      
  N stage (N,%)                                                     
  0                       154 (15.0%)   143 (92.9%)   11 (7.1%)     0.736
  1                       42 (4.1%)     38 (90.5%)    4 (9.5%)      
  2                       263 (25.7%)   237 (90.1%)   26 (9.9%)     
  3                       533 (52.0%)   474 (88.9%)   59 (11.1%)    
  x                       33 (3.2%)     30 (90.9%)    3 (9.1%)      
  M stage (N,%)                                                     
  0                       121(11.8%)    108 (89.3%)   13 (10.7%)    0.749
  1                       904(88.2%)    814 (90.0%)   90 (10.0%)    
  Lung metastases                                                   
  No                      645 (62.9%)   576 (89.3%)   69 (10.7%)    0.391
  Yes                     380 (37.1%)   346 (91.1%)   34 (8.9%)     
  Bone metastases                                                   
  No                      650 (63.4%)   577 (88.8%)   73 (11.2%)    0.106
  Yes                     375 (36.6%)   345 (92.0%)   30 (8.0%)     
  Brain metastases                                                  
  No                      841 (82.0%)   754 (89.7%)   87 (10.3%)    0.589
  Yes                     184 (18.0%)   168 (91.3%)   16 (8.7%)     
  Adrenal metastases                                                
  No                      942 (91.9%)   844 (89.6%)   98 (10.4%)    0.254
  Yes                     83 (8.1%)     78 (94.0%)    5 (6.0%)      
  Liver metastases                                                  
  No                      938 (91.5%)   849 (90.5%)   89 (9.5%)     0.061
  Yes                     87 (8.5%)     73 (83.9%)    14 (16.1%)    
  Pleural effusion                                                  
  No                      721 (70.3%)   645 (89.5%)   76 (10.5%)    0.495
  Yes                     304 (29.7%)   277 (91.1%)   27 (8.9%)     
  Pleural nodules                                                   
  No                      901 (87.9%)   813 (90.2%)   88 (9.8%)     0.425
  Yes                     124 (12.1%)   109 (87.9%)   15 (12.1%)    

ALK, anaplastic lymphoma kinase.

First‐line targeted therapy rate {#tca13090-sec-0015}
--------------------------------

First‐line targeted therapy was 73.8% (340/461) for patients harboring *EGFR* mutations and 51.4% (55/107) for patients with *ALK* rearrangements. There was a negative correlation between the first‐line targeted therapy rate and the *EGFR* mutation detection period (r = −0.152, *P* = 0.02), while no significant correlation was detected among patients with ALK rearrangement (r = −0.179, *P* = 0.076).

Discussion {#tca13090-sec-0016}
==========

The present study revealed that although adenocarcinoma was the most common pathological type to be submitted for *EGFR/ALK* evaluation, patients with squamous carcinoma had an *EGFR* mutation rate of 8.3% and an *ALK* rearrangement rate of 3.7%. Because of the relatively high mutation rate, patients with squamous cell carcinoma should also be routinely tested to determine their *EGFR* and *ALK* statuses.

Among four patients with squamous harboring *ALK* rearrangement, two showed inconsistent test results (positive for IHC and negative for FISH). Thus, IHC and FISH testing appear to provide inconsistent results regarding the squamous NSCLC patient\'s *ALK* status. Nevertheless, further validation of this result is needed, given the small sample size of this subgroup in the present study. A previous report regarding *ALK* rearrangement in NSCLC indicated that FISH provides higher sensitivity and specificity than IHC regarding the effects of targeted therapy, and that the interpretation of FISH results is more objective than that of IHC results.[17](#tca13090-bib-0017){ref-type="ref"} However, that study included a much smaller number of squamous cell carcinoma cases than adenocarcinoma cases (303 vs. 25 596). Therefore, further studies are needed to examine whether IHC and/or FISH are the most appropriate techniques for determining the *ALK* status, especially for patients with squamous cell carcinoma.

The present study revealed that the overall *EGFR* mutation rate was 40.7%, and gender, smoking history, and histology were independent predictors of *EGFR* mutation. These findings are consistent with the results of previous studies.[13](#tca13090-bib-0013){ref-type="ref"}, [14](#tca13090-bib-0014){ref-type="ref"}, [18](#tca13090-bib-0018){ref-type="ref"}, [19](#tca13090-bib-0019){ref-type="ref"}, [20](#tca13090-bib-0020){ref-type="ref"} Furthermore, we found that patients with *EGFR* mutations were more likely to have baseline brain metastases, which may be related to the downstream effects of *EGFR* on brain metastases. It is reported that *EGFR* inhibition decreased the rate of brain metastases in human DMA‐MB‐231 breast cancer cell lines. Although the patients with NSCLC were not evaluated, results suggested that *EGFR* may affect the phosphoinositide 3 kinase/protein kinase B/phospholipase Cγ pathway and subsequently lead to brain metastasis.[21](#tca13090-bib-0021){ref-type="ref"} Another study revealed that *EGFR*‐TKI therapy induced *MET* expression and phosphorylation, which may be associated with subsequent brain metastases in patients with NSCLC.[22](#tca13090-bib-0022){ref-type="ref"} While this relationship can only explain the increase in brain metastases after *EGFR*‐TKI treatment, it does not explain the relationship between *EGFR* mutations and baseline brain metastasis. Therefore, further studies are needed to better understand the relationship between *EGFR* mutations and baseline brain metastasis, and clinicians should be aware of this relationship when they encounter cases of *EGFR*‐mutated NSCLC, or cases with brain metastasis.

This study observed the *ALK*‐rearrangement rate was 9.4%, which is much higher than that reported among Asian patients with NSCLC of 4.1--5%.[23](#tca13090-bib-0023){ref-type="ref"} This difference may be related to the clinicopathological characteristics of the included patients. Previous reports indicated an *ALK* rearrangement rate of 13.5% (19/141) among patients with NSCLC who were female, Asian, did not smoke or smoked relatively small amounts, and adenocarcinoma.[16](#tca13090-bib-0016){ref-type="ref"}, [24](#tca13090-bib-0024){ref-type="ref"}, [25](#tca13090-bib-0025){ref-type="ref"}, [26](#tca13090-bib-0026){ref-type="ref"} In the present study, 85.8% (973/1134) of the enrolled patients had adenocarcinoma, which may explain the relatively high *ALK* rearrangement rate. The present study also revealed that only age was independently associated with *ALK* rearrangement, which is in line with previous reports.[27](#tca13090-bib-0027){ref-type="ref"}, [28](#tca13090-bib-0028){ref-type="ref"}

The study suggested that first‐line targeted therapy rate for patients with NSCLC with *EGFR*‐activating mutation or *ALK* rearrangement were still low. This relatively low *EGFR*‐TKI treatment rate could be explained by a long interval until the *EGFR* mutation is detected; thus, it may be possible to increase this rate by shortening the *EGFR* mutation detection period, which may be achieved by obtaining sufficient pathological specimens in a timely manner and popularizing *EGFR* gene detection technology. However, there was no significant correlation between the ALK rearrangement detection period and first‐line targeted therapy rate. Although the *ALK* rearrangement detection period was shorter than the *EGFR* mutation detection period (5 days vs. 7 days), the first‐line ALK‐TKIs treatment rate was lower than the first‐line EGFR‐TKIs treatment rate (51.4% vs. 73.8%). This finding may be related to limited access to ALK inhibitors, based on their high cost.

In addition to the important discoveries revealed in the present study, there are also some limitations. First, these data are preliminary, and thus additional follow‐up is needed to examine the effects of targeted therapy in cases of NSCLC harboring *EGFR* mutation or *ALK* rearrangement. Second, different centers had varying numbers of patients who were eligible for enrolment, and we were unable to perform regional subanalyses of *EGFR/ALK* status.

In summary, the present study demonstrated that patients with squamous cell carcinoma should also be routinely tested to determine their EGFR and ALK gene statuses. The first‐line targeted therapy rate remains low for Chinese patients with NSCLC harboring *EGFR*‐mutation and/or *ALK*‐rearrangement. First‐line targeted therapy for *EGFR*‐positive patients was negative associated with the time from the pathological diagnosis to EGFR gene status confirmation. Further research is needed to identify whether IHC and/or FISH are the most appropriate techniques for determining the *ALK* status of patients with squamous cell carcinoma.
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